GSK Study 115648 (MMR-160) "A Phase IIA, blinded, randomized, controlled, multinational consistency study to evaluate the immunogenicity and safety of GSK Biologicals'MMR Vaccine (209762) compared to Merck & Co. Inc.'s MMR Vaccine as a first dose, both c

  • Sarpong, Kwabena, (PI)

Project: Other project

StatusFinished
Effective start/end date1/7/131/6/16

Funding

  • GlaxoSmithKline Pharmaceuticals: $48,512.00